Federal Circuit Reverses and Remands in Barry v. DePuy Spinal Implant Patent Dispute

Case Overview

In a significant development for medical device patent litigation, the U.S. Court of Appeals for the Federal Circuit reversed and remanded the lower court’s decision in *Mark A. Barry v. DePuy* (Case No. 23-2226), a spinal surgery patent infringement dispute involving five issued U.S. patents and two commercially deployed orthopedic systems. Filed on August 1, 2023, and closed on January 20, 2026—after 903 days of litigation—the case centers on alleged infringement of patented spinal implant and surgical correction technologies by DePuy’s Expedium and Viper systems.

The Federal Circuit’s reversal signals that the original legal analysis contained reversible error, making this case a critical reference point for patent attorneys handling medical device infringement claims, IP professionals managing orthopedic technology portfolios, and R&D teams developing spinal surgery systems. The outcome underscores how appellate review continues to reshape the landscape of surgical instrument and implant patent litigation.

The Parties

The Patents at Issue

Five U.S. patents were asserted in this litigation, covering methods and apparatus relating to spinal alignment correction, multi-planar screw-rod constructs, and surgical techniques for treating spinal deformities:

• • US9668788B2 (App. No. 15/249,261)
• • US7670358B2 (App. No. 11/027,026)
• • US9339301B2 (App. No. 13/645,589)
• • US9668787B2 (App. No. 15/154,703)
• • US8361121B2 (App. No. 12/857,320)

The Accused Products

DePuy’s **Expedium Spine System** and **Viper System** were accused of infringing Barry’s patent claims. Both are widely used pedicle screw-rod fixation systems deployed in spinal fusion and deformity correction surgeries globally.

Legal Representation

Plaintiff Barry was represented by Kilpatrick Townsend & Stockton LLP and Stapleton Segal Cochran LLC, with a litigation team including Andrew William Rinehart, Courtney Dabbiere, Dario Alexander Machleidt, David Clay Holloway, Jonathan L. Cochran, Kathleen Geyer, and Mitchell G. Stockwell. No defendant counsel data was provided in the case record.

Litigation Timeline & Procedural History

The appeal was filed on August 1, 2023, before the U.S. Court of Appeals for the Federal Circuit. The case closed on January 20, 2026, reflecting a litigation duration of 903 days at the appellate level. The extended duration suggests the matter involved substantive briefing on multiple patent claims across five patents.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a REVERSED AND REMANDED disposition in *Barry v. DePuy*. This outcome means the appellate court identified legal error in the lower tribunal’s ruling and returned the matter for further proceedings consistent with its opinion. Specific damages amounts were not disclosed in the available case data.

Verdict Cause Analysis

The case was litigated as an infringement action. At the Federal Circuit level, reversals in infringement actions typically arise from one or more of the following legal grounds:

• Claim Construction Error: An incorrect interpretation of patent claim language by the lower court, which could materially alter the infringement analysis.
• Infringement Analysis: If an incorrect claim construction was applied, the resulting infringement determination would be tainted.
• Validity Challenges: Disagreement with how prior art was weighed or how the presumption of validity was applied against invalidity defenses.

Practitioners should consult the official Federal Circuit opinion via PACER or the USPTO Patent Center for the controlling legal rationale.

Legal Significance

A Federal Circuit reversal and remand in a five-patent medical device dispute carries meaningful precedential weight. The case may clarify claim construction methodology applicable to surgical method patents—an area where functional claim language and step-plus-function interpretations remain actively litigated. For orthopedic and spinal device IP, this outcome reinforces that appellate review remains a powerful corrective mechanism when district courts misapply claim construction doctrine.

Strategic Takeaways

For Patent Holders: Inventor-patentees asserting multi-patent portfolios against large device manufacturers should ensure claim language is drafted to clearly capture commercial product implementations. A reversal favoring the patentee on claim construction can revive infringement theories previously dismissed below.

For Accused Infringers: Early investment in Markman hearing strategy and expert claim construction testimony remains critical. Even a favorable district court ruling may be reversed if claim construction methodology is legally vulnerable on appeal.

For R&D Teams: Companies developing spinal fixation systems should conduct Freedom-to-Operate (FTO) analyses against inventor-held patent portfolios, not only large corporate IP estates. Barry’s five-patent family demonstrates that individual innovators can sustain complex, multi-year Federal Circuit litigation.

Industry & Competitive Implications

The *Barry v. DePuy* outcome carries broad implications for the **spinal surgery device market**, a sector projected to exceed $15 billion globally. DePuy’s Expedium and Viper systems are flagship commercial products, and a remand restoring infringement claims against these platforms creates ongoing commercial and legal uncertainty.

For **orthopedic device manufacturers**, this case reflects a persistent litigation trend: surgeon-inventors with foundational method patents challenging market-leading fixation systems. Companies relying on pedicle screw-rod architectures should audit their IP exposure against both issued and pending patents held by individual inventors and smaller portfolio entities.

From a **licensing perspective**, a remand outcome may incentivize settlement negotiations before the lower court re-adjudicates infringement, particularly given the litigation costs already incurred across 903 days of appellate proceedings. The Federal Circuit’s intervention signals that Barry’s claims survived appellate scrutiny on at least one material dimension.

For **IP portfolio managers** in the medical device space, this case reinforces the value of maintaining continuations and divisional applications across surgical method and implant design technology families—Barry’s five-patent portfolio across multiple application numbers exemplifies this strategy.

FAQ